Despite the known nephrotoxicity of gentamicin, the American Urological Association currently recommends a single perioperative gentamicin dose of 5 mg/kg for antimicrobial prophylaxis during urologic prosthetic surgery. This recommendation is based on the theoretical renal safety and increased antimicrobial activity of a single large dose. The goal of our investigation was to identify rates of acute kidney injury (AKI) in urologic prosthetic surgery both before and after adoption of weightbased gentamicin dosing.
INTRODUCTION AND OBJECTIVES:
Despite the known nephrotoxicity of gentamicin, the American Urological Association currently recommends a single perioperative gentamicin dose of 5 mg/kg for antimicrobial prophylaxis during urologic prosthetic surgery. This recommendation is based on the theoretical renal safety and increased antimicrobial activity of a single large dose. The goal of our investigation was to identify rates of acute kidney injury (AKI) in urologic prosthetic surgery both before and after adoption of weightbased gentamicin dosing.
METHODS: We performed a single-institution retrospective study of all patients receiving perioperative gentamicin during implant, revision, salvage, or explant of penile prostheses or artificial urinary sphincters between 2000 -2017. Patient characteristics and perioperative outcomes were identified. Patients with available preand postoperative ( 7 days) creatinine values were included. AKI was defined by Kidney Disease: Improving Global Outcomes criteria. Comparative analyses were performed between patients receiving standard-dose gentamicin and weight-based gentamicin.
RESULTS: Of 415 urologic prosthetic surgeries performed during the study period, 124 met inclusion criteria with paired pre-and postoperative creatinine values. Sixty-seven received standard-dose gentamicin and 57 received weight-based gentamicin [median dose 1.07 (IQR 1.04 -1.16) vs. 5.06 (IQR 3.96 -5.94) mg/kg IBW, p < 0.05]. There were no significant differences in preoperative renal function or various comorbidities between groups; however, the standard-dose group was younger [median age 61.0 (IQR 55.0 -66.0) vs. 64.0 (IQR 60.0 -68.5) years, p < 0.05], and comprised more explant cases (13.4 vs. 1.8%, p [ 0.01) than the weight-based group. Two of 67 (3.0%) in the standard-dose group vs. 9 of 57 (15.8%, p [ 0.02) in the weight-based group developed AKI (figure 1). Device infection rate was similar between standard-dose and weight-based groups (5.2 vs. 5.3%, p [ 1.00).
CONCLUSIONS: Our data suggest weight-based perioperative gentamicin dosing may be associated with an increased risk of AKI, without noticeably improving infection rates. Weight-based dosing may warrant closer perioperative monitoring of renal function, and merits larger investigations to determine risks and benefits. The most catastrophic complication of penile prosthesis surgery(PPS) is infection which is more common in diabetics. It was reported that glycosylated hemoglobin(HbA1c), as a marker for diabetic control, was correlated with infection rate.
OBJECTIVES: To check if the fasting blood sugar(FBS) at the time of PPS is correlated with the outcome.
METHODS: Based on a prospective study, we retrospectively analyzed the data of penile implant procedures in one full year (2015) in one facility. We excluded non-diabetics, revision surgery and procedures done by low volume surgeons. Preoperative, intraoperative and postoperative protocols were identical for all patients. We recorded all minor (oedema, echymosis, pain) and major (infection, erosion, mechanical failure) complications as early as 4 weeks and followed up to 3 years. A Likert scale questionnaire was completed by the patients at 1 year follow scored from 1-5 where 5 was very satisfied. STATA Release 13 was used for statistical analysis. T-test, Mann-Whitney U test and Pearson correlation were used. RESULTS: 218 patients had complete data and completed the study at follow up. The patient characteristics are summarized in Table 1 . Complications occurred in 6.25% of patients: 3.8% had infection and explantation, 0.9% had a superficial infection with successful conservative management, 0.9% had an erosion (one patient with associated infection) and 0.9% had mechanical failure (one patient with associated infection). The difference in HbA1c and FBS in patient with unremarkable postoperative course (HbA1c 7.9; FBS 152) or those with infective complications (HbA1c 8.6; FBS 183) did not reach statistical significance (p[0.06 and p[0.07, respectively) . The correlation between day of surgery FBS and HbA1c was weak (r[0.281; r2[0.0795) . Day of surgery FBS was within a 20 mg/dl range with what was expected based on HbA1c measurement in 62 patients (30%). The disparity between day of surgery FBS and expected FBS based on HbA1c was greater than 20 mg/dl in 146 (70%) patients.
CONCLUSIONS: Day of surgery FBS is only weakly correlated with HbA1c and did not predict the outcome of PPS.
